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Abstract: Over 10% of small-cell lung cancer (SCLC) patients have brain metastases (BM) 
at initial diagnosis; more than 50% will develop BM within 2 years. BM are detected in up to 
80% of all patients at autopsy. After primary treatment, prophylactic cranial irradiation (PCI) 
has been established as standard of care in SCLC patients responding to initial therapy. Based 
on level I evidence, PCI significantly decreases the risk of intracranial relapse and shows a 
modest survival benefit after 3 years. However, the role of PCI in defined patient subgroups 
such as resected SCLC, elderly and extensive stage patients with access to magnetic resonance 
imaging surveillance and stereotactic radiotherapy is yet to be fully clarified. Furthermore, 
strategies to effective prevention of neurocognitive decline after PCI remain unclear. All these 
factors significantly impact treatment decision making and should be evaluated in prospec-
tive settings. New concepts such as hippocampal avoidance and drug neuroprotection prevent 
chronic neurocognitive effects reducing treatment-related side effects of PCI. The aim of this 
review is to present a summary and update of the latest evidence for patient selection, efficacy 
and outcome of PCI.
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Introduction
Small-cell lung cancer (SCLC) is an aggressive type of cancer associated with poor 
prognosis due to rapid growth and early distant and loco-regional dissemination.1,2 
Combined modality treatment, consisting of chemotherapy and thoracic radiotherapy 
(TRT) delivered concurrently or sequentially, is the standard of care for primary dis-
ease.3 Patients who respond to initial therapy without developing symptomatic brain 
relapse will be treated with prophylactic cranial irradiation (PCI).4–6 In an earlier study 
in extensive stage (ES)-SCLC, PCI significantly reduced the incidence of symptomatic 
brain metastases (BM) by approximately 25%, which translated into improvement in 
median overall survival.6
Patients with limited stage (LS) achieve a median survival of 16–20 months and a 
5-year survival rate of 10%–20%. The administration of PCI has been investigated in 
several studies and has been proven to be an independent prognostic factor.6–8 In 2008, 
a small retrospective study first reported about the role of repeat contrast-enhanced 
cranial MRI immediately before the start of PCI for detection of occult intracranial 
relapse in patients who completed chemoradiotherapy.9 A randomized Phase 3 study 
by Le Péchoux et al established PCI with a total dose of 25 Gy delivered in 10 once-
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daily fractions as standard of care due to significant increase 
in mortality in the higher dose arm of 36 Gy.10 Interestingly, a 
pooled analysis by the North Central Cancer Group revealed 
a survival difference between PCI total dose of 25 and 30 
Gy probably associated with higher rates of adverse events 
in the 30 Gy group.11 Other prognostic factors such as age, 
sex, performance status and response to initial treatment 
were also reported to have an impact on patient outcome.12–16
Following 2 previous publications by Slotman et al, che-
motherapy followed by TRT and PCI in treatment respond-
ers was established as the new treatment standard for ES 
disease.6,17 However, a recent Phase 3 study conducted by 
Takahashi et al at 47 institutions in Japan included an active 
MRI surveillance program before and after PCI and could 
not confirm a survival benefit of PCI in ES disease with con-
firmed absence of BM.18 However, TRT was not an obligatory 
part of multimodal treatment in the study and has to be taken 
into account when interpreting the data.
Although the delivery of PCI in both LS- and ES-SCLC 
is considered to be well established, treatment-related side 
effects need further extensive investigation. PCI is known 
to be associated with acute side effects including alopecia, 
nausea, headache, fatigue as well as chronic neurologic 
sequelae such as decline in neurocognitive function.19 Sev-
eral strategies such as hippocampal avoidance and/or drug 
neuroprotection are currently being investigated in order to 
limit potential side effects.20–23
The aim of this review is to present a summary of the latest 
evidence for various patient subgroups, efficacy and outcome 
of PCI considering new technical and imaging opportunities.
PCi with hippocampal avoidance
Patient concern regarding neurotoxicity is the most com-
mon reason for PCI omission.23 Memory decline, changes 
in appetite, nausea, and vomiting as well as hair loss are a 
major treatment concern.
However, the diagnosis of SCLC generally appears to 
negatively impact health-related quality of life (QOL) in com-
parison to the normal population in several functions such as 
daily activity, physical functioning, cognitive and emotional 
functioning.24 A systematic review of literature published in 
2017 described that the impact on health-related QOL may 
be least in both LS- and ES-SCLC patients who responded 
to treatment, and greatest in ES patients who were treatment 
naïve.24 Importantly, QOL measured by patient-reported QOL 
scores after PCI showed a significant decline in QOL for up 
to 3 months after the completion of treatment.7
Prospective studies assessing QOL of patients in obser-
vation vs. PCI groups after initial treatment response are 
inconclusive. In the study by Le Péchoux et al, QOL was 
evaluated before PCI and routinely during follow-up up till 
3 years. PCI was associated with mild deterioration of com-
munication deficit, weakness of legs, intellectual deficit and 
memory dysfunction.10 However, further analyses reported 
that PCI was associated with a decline in Hopkins Verbal 
Learning Test-Revised (HVLT-R) and self-reported cognitive 
functioning. Additionally, due to the increased risk of devel-
oping chronic neurotoxicity in patients with 36 Gy, a total 
PCI dose of 25 Gy remains the standard of care for patients 
with LS-SCLC patients attaining a complete response to 
initial chemoradiotherapy.10,25
A randomized Phase 3 trial of PCI in patients with locally 
advanced non-small-cell lung cancer did not find any signifi-
cant differences in global cognitive function or QOL after PCI, 
but there was a significant decline in memory HVLT at 1 year.26
Importantly, a study by Simó et al revealed neuropsy-
chological deficits together with notable brain-specific 
structural changes after chemotherapy and PCI, suggesting 
that chemotherapy and especially PCI are associated with the 
development of cognitive and structural brain toxic effects.27 
Another study detected different markers of neuronal injury 
after PCI. These cerebrospinal markers such as neurofilament, 
T-tau or the levels of secreted amyloid precursor protein-α 
and -β could potentially be used to assess the individual risk 
of developing long-term symptoms of chronic encephalopa-
thy after PCI.28 However, prospective larger trials with robust 
neurocognitive assessments and longer follow-up periods are 
needed to confirm these results.
In order to prevent neurocognitive decline, important 
brain regions such as the limbic circuit and hippocampal 
formation should be identified as organs/regions at risk. These 
regions are in reasonable suspicion to be responsible for 
memory and higher neurocognitive function and are mainly 
represented in the hippocampal region. The incidence of BM 
in the perihippocampal region has not been well investigated. 
Only limited information is available and earlier studies show 
that metastasis incidence in the perihippocampal region can 
vary from 4% to 27%.20,21,29
Earlier studies estimated the perihippocampal metastasis 
risk at 8.6% and claimed safety of hippocampal avoidance 
during whole-brain radiotherapy (HA-WBRT) for clinical 
testing.21 However, in other studies focusing on hippocampal 
metastasis, Korkmaz et al reported a hippocampal metastasis 
rate of 32% and questioned the usage of HA-WBRT. The 
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prospective single-arm Phase-2 study (RTOG 0933) revealed 
that conformal avoidance of the hippocampus during whole-
brain radiotherapy (WBRT) is associated with preservation 
of memory using the HVLT-R and QOL.22 Unfortunately, the 
median survival time was short (less than 7 months) and the 
assessments were performed from baseline up to 6 months.
Another small prospective study by Redmond et al 
showed a median follow-up time of 16.7 months and a 2-year-
survival rate of 88%.20 Interestingly, there was no significant 
neurocognitive performance decline between baseline and 6 
or 12 months for any of the tests. Only two patients developed 
metastases in the underdosed region.
However, the patient collective was limited (n=20) and 
larger studies should determine the potential benefit of hip-
pocampal sparing.
Modern radiation techniques such as intensity-modulated 
radiotherapy permit administration of high radiation doses 
with avoidance of the perihippocampal regions. Neverthe-
less, the potential benefit of hippocampal sparing in limit-
ing the neurocognitive decline caused by brain irradiation 
must be questioned by an increase of failure in the spared 
regions. Additionally, the potential survival benefit of PCI 
is important, but maintaining QOL by avoiding the physical 
and neurocognitive complications should be critically dis-
cussed with the patient in order to enhance shared decision-
making.30 Currently, a host of randomized Phase 2/3 trials is 
underway to clarify this benefit including cognitive and QOL 
assessment (NCT02736916, NCT02906384/ZJCH-HA-PCI, 
NCT02397733, NCT01780675/M12PHA, NCT02635009/
NRG-CC003 trials)
In summary, HA-WBRT could prevent neurocognitive 
decline, but the incidence of metastases in perihippocampal 
regions after PCI should be critically evaluated. The results 
of ongoing Phase 3 trials are highly warranted to confirm 
the findings from smaller studies to fully endorse the routine 
usage of hippocampus avoidance in clinical practice.
PCi und drug neuroprotection
There are several substances in preclinical studies that have 
demonstrated a positive effect on neuroprotection. However, till 
date, only a few substances have been tested within the ramifi-
cations of a Phase 3 study. The RTOG 0614 trial randomized 
554 patients to receive placebo or the N-methyl-d-aspartate 
receptor antagonist memantine (20 mg/d) as a neuroprotectant, 
within 3 days of initiating radiotherapy for 24 weeks.
Memantine was well tolerated with a similar toxicity 
profile vs. placebo. In the memantine arm, there were fewer 
declines in delayed recall at 24 weeks, but the difference 
was non-significant. The memantine arm had significantly 
longer time to cognitive decline; the probability of cogni-
tive function failure at 24 weeks was 53.8% vs. 64.9% in 
the memantine vs. placebo arm. Superior results were seen 
in the memantine arm for executive function at 8 and 16 
weeks and for processing speed and delayed recognition at 
24 weeks.31 Although the primary endpoint was technically 
non-significant, the updated NCCN guidelines for manage-
ment of SCLC recommend considering memantine during 
and after administration of PCI.
In addition, donepezil, a neurotransmitter modulator 
was also evaluated in a Phase 3 placebo-controlled trial that 
randomized 198 brain tumor survivors ≥6 months after par-
tial- or whole-brain irradiation of which 8% underwent PCI 
to receive a single daily dose (5 mg for 6 weeks, 10 mg for 
18 weeks) of donepezil or placebo. The authors concluded 
that treatment with donepezil did not significantly improve 
the overall composite score (primary endpoint), but it did 
result in modest improvements in several cognitive functions, 
especially among patients with greater pre-treatment impair-
ments.32 Currently, there are a number of Phase 3 studies 
assessing the role of neuroprotectants within the context of 
PCI (NCT01553916, NCT00006349).
PCi in the elderly
Elderly patients are a rather interesting subgroup of SCLC 
patients. The proportion of elderly among all cases of SCLC 
has increased over the past 40 years.33 According to the 
Surveillance, Epidemiology, and End Results (SEER) data-
base, elderly patients (>70 years) among all cases of SCLC 
increased from 23% in 1975 to 44% in 2010. In general, 
elderly could be characterized by a lower performance status, 
higher comorbidity index, reduced organ function and less 
bone marrow reserve. Earlier studies have shown that elderly 
have significantly worse outcome compared to younger SCLC 
patients.34,35 Also, a large cohort study regarding therapeutic 
whole-brain irradiation reported significant toxicity such as 
neurocognitive dysfunction with memory loss in patients 
older than 70 years.36 In this context, elderly patients are 
the focus of research to reduce treatment-related toxicity of 
cranial irradiation and improve prognosis.
Historical studies reported that older patients (>60 years) 
experience a greater risk of acute and chronic neurotoxicity 
after PCI, as well as patients treated with higher total dose 
(>30 Gy) or concurrent chemotherapy.37–39 Previous data 
from randomized trials and a meta-analysis4,6,11,18 included 
a varying number of older patients, which should be taken 
into consideration.
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The landmark study by Aupérin et al evaluated 987 
patients from 7 studies focusing on oncologic outcome of 
PCI.4 Over 25% of all analyzed patients could be defined as 
elderly patients (≥65 years). In the study by Le Péchoux et al, 
age (≤60 vs. >60 years) was a stratification factor for random-
ization.11 Unfortunately, the percentage of older patients in 
the analysis was not reported. Slotman et al included patients 
older than 75 years in their study, which represented over 
7.5% of all participants.17
The SEER database analysis (1926 patients) published by 
Eaton et al focusing on elderly SCLC patients aged ≥75 years 
confirmed application of PCI as an independent predictor of 
overall survival.40 However, the study did not report toxicity 
data for this patient subgroup.
A retrospective analysis of 658 LS SCLC patients from 
MD Anderson Cancer Center revealed that PCI conferred no 
survival benefit for patients aged ≥70 years and explained it 
with an increased risk of death from other comorbidities and 
extracranial disease progression.36
In Takahashi et al’s study, about 47% of patients in the 
PCI group and 46% in the observation group were aged 70 
years or older.18 Takahashi et al found no overall survival 
benefit when administering PCI versus observation. Their 
suggestion is that PCI in patients with extensive-disease 
SCLC and confirmed absence of BM should be judged 
carefully because of the risk of declining cognitive func-
tion. Especially older patients appear to be at a higher risk 
of neurocognitive decline.
In summary, there is inconsistent data for PCI in elderly. 
The usage of PCI in this subgroup should be critically evalu-
ated according to the stage of disease, treatment response to 
initial therapy, performance status, and existing general and 
neurological comorbidities. Data on the survival benefit of 
PCI in elderly are rather limited due to underrepresentation 
of this subgroup in prospective clinical trials.41
PCi in resected early-stage SCLC
Another relevant issue worth addressing is the issue of PCI 
in resected p-stage I SCLC.
The NCCN and European Society for Medical Oncol-
ogy guidelines recommend adjuvant chemotherapy and PCI 
for early-stage SCLC, irrespective of primary treatment 
approach. We previously addressed this issue in two previous 
communications.42,43
Stahl et al demonstrated in an analysis of the National 
Cancer Data Base (NCDB) a surge in the utilization of sur-
gery in 2004 vs. 2013, up from 14.9% to 28.5%.44 The paucity 
of evidence suggests that surgery is feasible in clinical stage 
I disease. However, careful selection of candidates including 
rigorous preoperative staging should be performed (positron 
emission tomography with 2-deoxy-2-[fluorine-18]fluoro-d-
glucose integrated with computed tomography, endobron-
chial ultrasound-guided transbronchial needle aspiration 
and/or mediastinoscopy, comprehensive brain imaging using 
contrast-enhanced MRI) in order to ascertain stage I disease.
Current evidence supports adjuvant chemotherapy fol-
lowing surgery and is endorsed by another NCDB analysis 
by Yang et al in patients with pT1-2N0M0 disease, which 
demonstrated that these patients had inferior outcomes than 
those who underwent resection with adjuvant treatment.45
Regarding PCI in these patients, there is some evidence 
albeit retrospective data suggesting omission of PCI exclu-
sively in the group of patients with p-stage I disease as various 
studies have shown a relatively low cumulative incidence of 
BM, in the order of 10%.42 However, due to the paucity of 
data and expected discrepancies in the prevalence of BM, 
this recommendation does not extend to patients with clini-
cal stage I disease.
PCi in eS-SCLC
The most intense debate recently has centered on univer-
sal delivery of PCI particularly in ES-SCLC. In an era in 
which there was a paucity of data regarding PCI delivery in 
these patients, the EORTC study by Slotman et al in 2007 
demonstrated a reduction in risk of BM in the PCI group, 
cumulative risk of BM within 1 year of 14.6% and 40.4% 
in the PCI vs. control group, 1-year survival rate of 27.1% 
vs. 13.3% in the PCI vs. control group, association of PCI 
with an increase in median disease-free survival from 12.0 
weeks to 14.7 weeks and an increase in median OS from 5.4 
months to 6.7 months from randomization.6
However, the recently published Japanese study by Taka-
hashi et al has sparked renewed debate. The study randomized 
224 patients between 2009 and 2013 to PCI vs. observation. 
In the planned interim analysis on June 18, 2013, of the first 
163 enrolled patients, Bayesian predictive probability of 
PCI, being superior to observation, was 0.011%, resulting 
in early termination of the study due to futility. In the final 
analysis, median OS from randomization was 11.6 months 
in the PCI group vs. 13.7 months in the observation group. 
The authors concluded that PCI could be omitted in therapy 
responders under the premise that these patients be followed 
up comprehensively by serial brain imaging and radiotherapy 
be deferred till onset of BM.18
Both studies have been studied methodically and defin-
ing shortcomings have been leveled against both studies, 
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which have been discussed extensively in various previous 
publications,18,46–49 particularly in the original publication by 
the Japanese group18 as well as a recently published review 
article by the same group.48
Most noteworthy was the mandated comprehensive brain 
imaging scheduling in the Japanese study, whereas in the 
EORTC study, CT/MRI of the brain was only performed 
in symptomatic patients. As such, only 29% of randomized 
patients in the EORTC study received brain imaging at diag-
nosis, and the number of patients who received repeat brain 
imaging prior to PCI is unclear.
Critics of the EORTC study partly attribute the survival 
benefit to the possible presence of subclinical BM before 
randomization, ascribing improved median OS to cranial irra-
diation. In addition, it is unclear what proportion of patients 
in the EORTC trial received  platinum-based chemotherapy 
as mandated in the Japanese trial.
Moreover, various fractionation schedules at the discre-
tion of the participating centers were adopted in the EORTC 
study with the predominant schedule being 20 Gy delivered in 
five fractions in 88/143 patients. By contrast, 25 Gy was uni-
versally delivered in 10 daily fractions in the Japanese trial.
However, the publication by Takahashi et al is not without 
its flaws. It is inevitable to question whether careful patient 
selection might have played a role as previously described 
in a previous communication by Slotman.46 On an average, 
participating centers enrolled only one patient per year and 
the high proportion of patients who received second-, third- 
and fourth-line chemotherapy is incongruent with previ-
ously published data49 and might reflect this assumption. 
In addition, in stark contrast to the EORTC trial, a higher 
proportion of patients received radiotherapy in the observa-
tion arm of the Japanese trial (25% vs. 58%). Le Péchoux et 
al described extensively similar 1-year survival rates in the 
subgroup analysis of ES-SCLC patients of the landmark PCI 
meta-analysis published in 1999.4,49 Differences in survival 
outcome between both studies were also attributed to sev-
eral factors including eligibility criteria, patient selection, 
treatment regimens (chemotherapy and PCI fractionation), 
demographics as well as possibly related to host-related 
genetic differences in SCLC between Asian and non-Asian 
populations.49
However, a retrospective study emanating from Germany 
demonstrated a stark improved median overall survival after 
PCI in ES-SCLC patients in comparison to the EORTC trial 
(12 vs. 6.7 months) and similar to the results of the Japanese 
trial.50 However, as the authors duly noted, according to insti-
tutional policy, the study population comprised a select group 
of patients with relatively good performance status (median 
ECOG 1) with exclusion of older patients and patients at 
high risk for cognitive decline.
PCi vs. active MRi surveillance with 
access to stereotactic radiotherapy (SRT)
Based on the conflicting results of the EORTC and Japanese 
trials, the NCCN softened its latest recommendation for 
PCI in ES-SCLC to “consider”. However, in patients not 
receiving PCI, a comprehensive MRI surveillance program 
in accordance with the above-mentioned study is paramount.
Furthermore, there is uncertainty regarding use of SRT 
for brain relapse (single or multiple) in SCLC. There are 
some retrospective data supporting its use.
A secondary analysis of the Japanese trial noted that 25/54 
(46%) patients in the PCI arm received repeat radiotherapy 
with stereotactic radiosurgery (SRS) the preferred modality 
as is popularly adopted in the authors’ country of origin.51
In a recent NCDB analysis of 5952 SCLC patients by 
Robin et al, upfront SRS was associated with improved 
median OS vs. upfront WBRT +/− SRS (10.8 vs. 7.1 months, 
HR 0.65, 95% CI 0.55–0.75, p <0.001), which persisted on 
multivariate analysis controlling for comorbidities, extra-
cranial metastases, age, race/ethnicity and sex (HR 0.70, 
95% CI 0.60–0.81, p <0.001). However, the results must be 
interpreted with caution as the SRS arm was underpowered 
with 200 vs. 5752 patients in the WBRT arm.52
Also in patients with single brain metastasis, Bernhardt 
et al recently described prognostic factors and demonstrated 
in a retrospective analysis of 52 patients that, prior surgery, 
synchronous as opposed to metachronous metastasis and 
response to primary chemotherapy was associated with 
improved OS.53
Currently, a Phase 2 study in Germany comparing WBRT 
alone to SRS for SCLC patients is recruiting to this effect 
(NCT03297788) and might provide a basis for further inves-
tigation of this strategy within the ramifications of a Phase 
3 study.
Conclusion
It is imminently paramount that the TNM classification 
according to the UICC 8th edition is universally adopted for 
SCLC.54 Subsequently, survival benefit conferred by PCI in 
LS-SCLC could be further elucidated.
Since its initial proposal for SCLC in 1973 and recom-
mendation in 1999, PCI has been the topic of recurring 
interest and debate. It is inevitable that we are slowly arriving 
at a defining crossroad as new data emanating from studies 
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in the current MRI era and ubiquity of comprehensive brain 
imaging suggest that the modest survival benefit alluded 
to PCI may be less than previously anticipated, especially 
in ES-SCLC. Thus, further studies are urgently required to 
dispel these uncertainties.
However, the best strategy moving forward is probably 
integrating hippocampal avoidance and drug neuroprotec-
tion to minimize neuropsychological sequelae. Addition-
ally, regarding the question of PCI in the elderly, there are 
some question marks that remain but, in our opinion, shared 
 decision making is the pinnacle of patient-centered care. Sub-
sequently, the next step, strictly hypothesis-generating would 
be evaluating possible dose de-escalation in elderly patients.
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